• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    DCAT Week ’19

    Temperature-Controlled Logistics

    Reducing Pill Burden

    Nasal Drug Delivery

    AI in Pharma: Transforming Data into Drugs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    BASi Appoints COO

    Nestlé Health Licenses Codexis’ CDX-6114

    SK, Arvelle Sign $530M Deal for Antiepileptic Drug

    GS1 Delivers Lightweight Messaging Standard For Verification of Product Identifiers

    Progenics Launches Mfg. Ops in NJ
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Progenics Launches Mfg. Ops in NJ

    Pelican BioThermal Opens New Network Location

    Reed-Lane Facility Tour

    Haselmeier Acquires Drug Manufacturing License

    Emerald Health, Lonza Enter Large-Scale Mfg. Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    GS1 Delivers Lightweight Messaging Standard For Verification of Product Identifiers

    Pelican BioThermal Opens New Network Location

    Reed-Lane Facility Tour

    Recipharm Facilities Ready for EU Serialization

    Andrew Alliance, Sartorius Launch Research Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Nestlé Health Licenses Codexis’ CDX-6114

    Personalized Medicine: Getting More Out of Clinical Trials

    SK, Arvelle Sign $530M Deal for Antiepileptic Drug

    Charles River to Pay $510M for Citoxlab

    West, Swissfillon Enter Drug Delivery Partnership
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Former FDA Senior Executives Join PAREXEL

    Top Global Pharma Company to Implement ValGenesis' VLMS

    WCG, Prudentia Enter Pharmacovigilance Alliance

    ValGenesis VLMS Chosen to Digitize Validation Process

    Serialization Compliance: Understanding the Challenges
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Jubilant HollisterStier Contract Manufacturing & Services

    Federal Equipment Company

    Alcami

    Reed-Lane, Inc.

    Emergent BioSolutions, Inc.
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions, Inc.

    Alcami

    Emergent BioSolutions, Inc.

    Vetter Pharma International GmbH

    Ascendia Pharmaceuticals
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Allergan to Acquire Bonti for $195M

    Adds new neurotoxin programs to medical aesthetics pipeline

    Related CONTENT
    • Inovio, ApolloBio Close VGX-3100 Collaboration
    • XBiotech USA, CTA Sign License Agreement
    • Therapure Biopharma Launches Biologics Division
    • Accelovance, Linical Enter Merger
    • Arena Pharmaceuticals, Outpost Medicine Enter Agreement
    09.14.18
    Allergan has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications, for an upfront payment of $195 million and additional potential commercial milestone payments.
     
    Following completion of the acquisition, Allergan will obtain global rights to Bonti's pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development, EB-001A (aesthetic) and EB-001T (therapeutic). The active ingredient in both programs, EB-001, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical profile, characterized by a rapid onset of action within 24 hours and a 2 to 4-week duration of effect. Bonti recently announced topline results of the first clinical study of EB-001 in glabellar frown lines. The study confirmed both the safety and efficacy of the differentiated profile.
     
    In the U.S. there are currently approximately 65 million consumers who are considering facial injectable treatments, including some who may be interested in being treated with a faster acting shorter-duration product.
     
    "The acquisition of Bonti is a strategic investment for the future of our medical aesthetics business and has the potential to enhance our best-in-class medical aesthetics pipeline," said Brent Saunders, chairman and chief executive officer, Allergan. "With the medical aesthetics market vastly expanding, a fast-acting neurotoxin with a 2 to 4-week duration will be an attractive option for consumers, particularly those who are considering a medical aesthetics treatment for the first time."
     
    "We're excited about the development and commercial prospects for our novel programs within Allergan's leading medical aesthetics portfolio," said Fauad Hasan, chief executive officer and co-founder at Bonti. "The promise of benefitting more consumers worldwide with our novel neurotoxin programs plus Allergan's stature and resources in this market will help realize our team's and investors' aims. We could not envision a more compelling acquirer or better strategic fit."
    Related Searches
    • pipeline
    • Development
    • acquisition
    • study
    Suggested For You
    LakePharma Announces "New Frontiers in Biologics" Conference LakePharma Announces "New Frontiers in Biologics" Conference
    Allergan, Editas Announce Exercise of Development Options Allergan, Editas Announce Exercise of Development Options
    Financial Report: Allergan Financial Report: Allergan
    06	NOVARTIS 06 NOVARTIS
    18	ALLERGAN 18 ALLERGAN
    13	Teva 13 Teva
    11	Amgen 11 Amgen
    Endocyte, ITG Enter Supply Deal Endocyte, ITG Enter Supply Deal
    Ajinomoto Althea Makes Key VP Hires Ajinomoto Althea Makes Key VP Hires
    Millicent Pharma Launches Operations Millicent Pharma Launches Operations
    Allergan to Acquire Aptinyx Compound  Allergan to Acquire Aptinyx Compound
    Tedor Pharma Makes Organizational Changes  Tedor Pharma Makes Organizational Changes
    Takeda to Acquire Shire in $62B Deal Takeda to Acquire Shire in $62B Deal
    Arena Pharmaceuticals, Outpost Medicine Enter Agreement Arena Pharmaceuticals, Outpost Medicine Enter Agreement
    Accelovance, Linical Enter Merger Accelovance, Linical Enter Merger

    Related Breaking News

    • Breaking News | Drug Development | Industry News
      Nestlé Health Licenses Codexis’ CDX-6114

      Nestlé Health Licenses Codexis’ CDX-6114

      Novel, oral enzyme for phenylketonuria is Codexis’ first internally developed biotherapeutic candidate
      02.19.19

    • Bio News | Breaking News | Collaborations & Alliances | Drug Development | Industry News
      SK, Arvelle Sign $530M Deal for Antiepileptic Drug

      SK, Arvelle Sign $530M Deal for Antiepileptic Drug

      Mark Altmeyer named president and chief executive of Arvelle
      02.15.19

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | Laboratory Testing | R&D
      Passage Bio Officially Launches

      Passage Bio Officially Launches

      With $115.5M Series A, to develop AAV-delivered therapeutics to treat rare monogenic CNS diseases
      02.15.19


    • Bio News | Collaborations & Alliances | Drug Development | Industry News | Methods Development | R&D
      Axovant Announces Formation of Arvelle Therapeutics

      Axovant Announces Formation of Arvelle Therapeutics

      Along with the strategic transition of legacy small molecule team into the newly formed company
      02.15.19

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      AbCellera & Novartis Announce Collaboration

      AbCellera & Novartis Announce Collaboration

      AbCellera to apply technology to advance programs on up to ten targets elected by Novartis
      02.15.19

    • Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      NeoTX, MedImmune Announce Clinical Collaboration

      NeoTX, MedImmune Announce Clinical Collaboration

      To support Phase 1b/2 studies investigating ANYARA in combination with AstraZeneca's IMFINZI
      02.11.19


    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      Eton & Sintetica Enter Supply Agreement

      Eton & Sintetica Enter Supply Agreement

      To obtain U.S. marketing rights to two high-volume, near-term product launch candidates.
      02.11.19

    • Bio News | Breaking News | Collaborations & Alliances | Drug Development | Industry News
      3SBio, Verseau Establish Immuno-Oncology Devt. Collaboration

      3SBio, Verseau Establish Immuno-Oncology Devt. Collaboration

      3SBio will fund and conduct antibody development and GMP manufacturing
      02.11.19

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      MedPharm & Palvella Expand Partnership

      MedPharm & Palvella Expand Partnership

      For developing a new treatment for the debilitating rare disease, pachyonychia congenita
      02.11.19


    • Breaking News | Drug Development | Industry News
      IFM Therapeutics Launches Subsidiary

      IFM Therapeutics Launches Subsidiary

      IFM Due to advance cGAS/STING antagonists for serious inflammatory and autoimmune diseases
      02.11.19

    • Bio News | Collaborations & Alliances | Drug Development | Industry News | R&D
      Pathios, Sygnature Announce Partnership

      Pathios, Sygnature Announce Partnership

      For an integrated drug discovery program against a novel G Protein-Coupled Receptor (GPCR) target
      02.07.19

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      Evotec & Galapagos Enter Global Collaboration

      Evotec & Galapagos Enter Global Collaboration

      Focused on a novel target for fibrosis and other indications
      02.07.19

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      EMD Serono Expands Bio R&D Facility

      EMD Serono Expands Bio R&D Facility

      Will invest $70 million to expand Billerica, MA facility with a new 145,000 sq.-ft. building
      02.06.19

    • Bio News | Breaking News | Collaborations & Alliances | Drug Development | Industry News
      MilliporeSigma Funds Small Biotechs

      MilliporeSigma Funds Small Biotechs

      Awards grants to biotechs tackling cancer and cardiovascular disease
      02.05.19

    • Bio News | Collaborations & Alliances | Drug Development | Industry News
      Taiho and Cullinan Enter Cancer Collaboration

      Taiho and Cullinan Enter Cancer Collaboration

      Will develop TAS6417, novel EGFR tyrosine kinase inhibitor
      02.05.19

    Breaking News
    • BASi Appoints COO
    • Nestlé Health Licenses Codexis’ CDX-6114
    • SK, Arvelle Sign $530M Deal for Antiepileptic Drug
    • GS1 Delivers Lightweight Messaging Standard For Verification of Product Identifiers
    • Progenics Launches Mfg. Ops in NJ
    View Breaking News >
    CURRENT ISSUE

    January/February 2019

    • DCAT Week ’19
    • Temperature-Controlled Logistics
    • Reducing Pill Burden
    • Nasal Drug Delivery
    • AI in Pharma: Transforming Data into Drugs
    • Digitization: Pharma 4.0
    • Serialization Compliance: Understanding the Challenges
    • FDA & Data Integrity
    • Rising Demand for Lyophilized Products
    • Future Trends in the CDMO Space
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • privacy policy
    • term and condition
    • about us
    • contact us

    follow us

    Subscribe

    magazines

    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login